Integrated chemical molecular docking with network pharmacology to study the molecular mechanism of JianPi YiQi BuSui method for treating myasthenia gravis

Treatment of myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder, remains challenging due to side effects associated with modern medications used to treat the disease. JianPi YiQi BuSui Method (JPYQBSM) is a traditional Chinese medicine (TCM) which has been shown to provide pivotal MG-alleviating therapeutic benefits. However, JPYQBSM active chemical components and molecular mechanisms and therapeutic targets have not yet been comprehensively investigated, prompting this study. The pharmacodynamic basis and action mechanism of JPYQBSM in the treatment of myasthenia gravis were predicted by computer network pharmacological technology and molecular docking technology of chemical composition. JPYQBSM alleviated MG through multi-chemical component, multitarget and multi-pathway synergistic therapeutic effects. This study provides new insights into specific mechanisms underlying JPYQBSM therapeutic effects for alleviating MG.